articleTop 1% cited

Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III

Schizophrenia Research · 2005 · Vol. 80(1) · pp. 19–32

Joseph P. McEvoy✉(Duke University)Jonathan M. Meyer(University of California, San Diego)Donald Goff(Harvard University Press)Henry A. Nasrallah(University of Cincinnati)Sonia M. Davis(IQVIA (United States))Lisa SullivanHerbert Y. Meltzer(Vanderbilt Psychiatric Hospital)John Hsiao(National Institutes of Health)T. Scott Stroup(University of North Carolina at Chapel Hill)Jeffrey A. Lieberman(Columbia University)

View via DOI Publisher page

Schizophrenia research and treatment Diet and metabolism studies Diabetes, Cardiovascular Risks, and LipoproteinsNational Health and Nutrition Examination SurveyMedicineInternal medicineWaistSchizophrenia (object-oriented programming)AntipsychoticBody mass indexLogistic regressionMetabolic syndromePsychiatry

MeSH terms

AdultAgedAnthropometryAntihypertensive AgentsClinical Trials as TopicFastingFemaleHumansHypertensionInsulinCholesterol, HDLMaleMiddle AgedObesityProspective Studies

Citations

1,134

FWCI

33.31

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline